Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACP augmentation during ACL reconstruction for semitendinosus donor-site healing
ACTRN12618000762257Phase 4Recruiting
- Sponsor
- Griffith University
- Start
- Jun 2024
- Countries
- 1
01
Overview
Phase 4, open-label trial of autologous conditioned plasma in Anterior cruciate ligament deficiency (ACL) (2 arms), sponsored by Griffith University. Primary endpoint: Isometric knee flexion strength. Started Jun 2024; status: recruiting.
02
Drugs
autologous conditioned plasma
03
Conditions
Anterior cruciate ligament deficiency (ACL)
Beyond the preview
Go deeper on ACTRN12618000762257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000762257.